CN107041882A - Application of the corter pseudolaricis acetic acid in anti-fibrosis drug is prepared - Google Patents
Application of the corter pseudolaricis acetic acid in anti-fibrosis drug is prepared Download PDFInfo
- Publication number
- CN107041882A CN107041882A CN201610932447.1A CN201610932447A CN107041882A CN 107041882 A CN107041882 A CN 107041882A CN 201610932447 A CN201610932447 A CN 201610932447A CN 107041882 A CN107041882 A CN 107041882A
- Authority
- CN
- China
- Prior art keywords
- acetic acid
- corter pseudolaricis
- fibrosis
- pseudolaricis acetic
- lung tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses application of the corter pseudolaricis acetic acid in anti-fibrosis drug is prepared, shown in the corter pseudolaricis acetic acid structure formula (I)：
Description
Technical field
The present invention relates to application of the corter pseudolaricis acetic acid in anti-fibrosis drug is prepared.
Background technology
Idiopathic pulmonary fibrosis (idiopathic pulmonary fibrosis, IPF) refer to alveolar epithelial cells by
Repaired extremely after damage, cause proliferation of lung fibroblast to be converted to myofibroblast, Extracellular Matrix Secretion is excessive, collagen
Deposition, alveolar structure changes, and ultimately forms fibrosis.Not yet completely clearly, research at present is thought should with oxidation for its pathogenesis
Sharp, inflammatory reaction, Humoral immunity feritin-angiotensins-RAAS (RAAS) are closely related[1-3].Oxidative stress is produced
Raw excessive ROS causes pulmonary epithelial cells necrosis to induce inflammatory reaction and cytokine network imbalance promotion interleukins, turn
Change the increase such as grouth factor beta 1 (TGF-β 1), CTGF (CTGF), inflammatory reaction can produce active oxygen metabolism again
Product and a series of inflammatory mediators aggravate inflammation and pulmonary epithelial cells necrosis, form vicious circle, add pulmonary fibrosis progressive
Weight[4].It is now recognized that RAAS systems are played an important role in pulmonary fibrosis process, angiotensin converting enzyme
AngiotensinⅠ (Angiotensin I, Ang I) can be hydrolyzed to by (Angiotensin converting enzyme, ACE)
AngiotensinⅡ (Angiotensin II, Ang II), Ang II plays important in the generation, evolution of various inflammation
Effect.And aldosterone can stimulate cell mitogen and collage synthesis, promotion organization cell increases, and increase collagen sinks
Product, strengthens the repair ability of tissue.Patient is diagnosed as IPF, less than 3 years from respiratory failure to death, and 5 years survival rates are about
For 20%, treatment is still without specific drug at present[1]。
Corter pseudolaricis acetic acid (pseudolaric acid B, PLAB) is from China pinaceae plant golden larch (pseudolarix
Kaempferi Gord) root skin and nearly root skin (corter pseudolaricis) in one of the main component isolated, be diterpene-kind compound.My god
Many compounds with this class formation have significant antitumor action in right product[5-6].PLAB also has significant anti-true
Bacterium activity[7-8].At present, not yet there is the report that corter pseudolaricis acetic acid is applied in anti-fibrosis drug is prepared.
The content of the invention
The purpose of the present invention is to overcome the deficiencies in the prior art preparing anti-fibrosis drug there is provided a kind of corter pseudolaricis acetic acid
In application.
Second object of the present invention is to provide a kind of preparation containing corter pseudolaricis acetic acid in anti-fibrosis drug is prepared
Using.
Technical scheme is summarized as follows：
Application of the corter pseudolaricis acetic acid in anti-fibrosis drug is prepared, shown in the corter pseudolaricis acetic acid structure formula (I)：
Application of the preparation containing corter pseudolaricis acetic acid in anti-fibrosis drug is prepared, the agent of the preparation containing corter pseudolaricis acetic acid
Type is tablet, capsule, granule or injection.
It is demonstrated experimentally that corter pseudolaricis acetic acid (pseudolaric acid B, PLAB) substantially mitigates the lung fibre that bleomycin is built
The pulmonary alveolitis and pulmonary fibrosis degree of dimensionization model mice, can suppress IL6/TGF- β 1/P-smad2 in the lung tissue of fibrosis and lead to
The expression on road, makes collagen secretion in lung tissue, and α-SMA and TGF-β 1, P-Smad2 protein expressions are significantly reduced, thus treat and
Prevent pulmonary fibrosis.
Brief description of the drawings
Mouse lung tissue pathological section (× 200) after the effect of Fig. 1 corter pseudolaricis acetic acids.
Mouse lung tissue pathological section scores after the effect of Fig. 2 corter pseudolaricis acetic acids.
Fig. 3 each group mouse lung tissues Masson dyeing observations (× 200).
Mouse lung tissue Masson dyeing scoring after the effect of Fig. 4 corter pseudolaricis acetic acids.
Each group blood serum IL-6 content after the effect of Fig. 5 corter pseudolaricis acetic acids.
Each group TNF-α content after the effect of Fig. 6 corter pseudolaricis acetic acids.
The influence of mouse lung tissue Collage Ⅲ glomerulopathy after the effect of Fig. 7 corter pseudolaricis acetic acids.
The influence of mouse lung tissue Collage Ⅲ glomerulopathy after the effect of Fig. 8 corter pseudolaricis acetic acids.
Mouse lung tissue α-SMA influence after the effect of Fig. 9 corter pseudolaricis acetic acids.
The influence of mouse lung tissue TGF-β 1 after the effect of Figure 10 corter pseudolaricis acetic acids.
Mouse lung tissue P-smad2 influence after the effect of Figure 11 corter pseudolaricis acetic acids.
Embodiment
Following embodiment and method can make professional and technical personnel that the present invention is more fully understood, but not with any side
The formula limitation present invention
Corter pseudolaricis acetic acid extracting method is as follows：
It is heated to reflux extracting from corter pseudolaricis with the ethanol water that volumetric concentration is 95% and obtains crude product, then uses acetic acid second
Ester extracts crude product, obtains ethyl acetate extract layer.Then isolated and purified by silicagel column.Through thin-layer chromatographic analysis, selection
The elution ratio of mobile phase：Silica CC (Φ 35cm, 2.5cm), petroleum ether：Ethyl acetate=6:1, isolated sterling
PLAB (90%).
Pharmacological experimental data：
The research that corter pseudolaricis acetic acid is acted in anti-fibrosis drug is prepared：
1 materials and methods
1.1 experimental animals and material
4 SPF grades of week old male mouse of kunming 40 (Beijing Vital River Experimental Animals Technology Co., Ltd.), body weight (21
±2.0)g；
Normal saline is used before corter pseudolaricis acetic acid white powder, administration；
Pirfenidone：Tianjin Kingyork Pharmaceutical Co., Ltd. (Chinese medicines quasi-word H12020392)；
Hydrochloride for injection bleomycin, Nippon Kayaku K. K, lot number 640412, import of drugs registration certificate number：
H20090885；
Superoxide dismutase (SOD) testing cassete, glutathione (GSH) kit and hydroxyproline (HYP) kit are equal
Graduate School of Engineering is built up purchased from Nanjing；
The rabbit polyclonal antibody of TGF-β 1 (ab92486), P-smad2 rabbit monoclonal antibodies (ab188334), α-SMA rabbits Dan Ke
Grand antibody (ab23575) is purchased from Abcam companies；
Secondary antibody is purchased from Beijing Bioisystech Co., Ltd of Zhong Shan Golden Bridge.
1.2 method
1.2.1 packet and modeling mouse are randomly divided into 4 groups：Compare (N) group, model (M) group, positive drug pirfenidone (P)
Group, corter pseudolaricis acetic acid (T) group, every group 10.
N groups tracheal strips instill 0.9% sodium chloride injection, and remaining each group mouse transtracheal gives bleomycin solution
5mgkg-1 sets up pulmonary fibrosis model.
The 2nd day group gives pirfenidone (50mgkg after modeling-1·d-1), corter pseudolaricis acetic acid (5mgkg-1·d-1) gavage.
N groups fill isometric 0.9% sodium chloride injection with M groups.
1.2.2 sample is obtained with analyzing in 10 materials of every group of execution in the 21st day after treatment.Each group eyeball of mouse takes blood,
Serum is left and taken to detect.Then take off neck and put to death quick opening mouse thoracic cavity, cut the middle lobe of right lung, 4% neutral formalin is fixed, and is HE
Dyeing and Masson coloring pathological sections.Remaining -80 DEG C of lung tissue, which freezes, makees index of correlation measure.
1.2.3 pathologic state colony observation observation pulmonary morphology, with reference to methods such as Szapiel, is dyed to lung tissue HE
As a result alveolar inflammation scoring is carried out.
Pulmonary alveolitis is classified and standards of grading:
0 grade：Without pulmonary alveolitis, 0 point is remembered；
1 grade：Alveolar septa infiltration is seen under slight pulmonary alveolitis, mirror and is thickened, but extent of disease is no more than full lung 20%, alveolar knot
Significant change does not occur for structure, remembers 1 point；
2 grades：Moderate pulmonary alveolitis, alveolar inflammation lesion area accounts for the 20%-50% of full lung, remembers 2 points；
3 grades：Severe pulmonary alveolitis, extent of disease exceedes 50% that full facies pulmonalis cordis is accumulated, the visible inflammatory cell of alveolar space and red blood cell,
3 points of note.
Graphical analysis is carried out to Masson coloration results with Image ProP lus softwares, every section randomly selects 5
Overlapped view (× 200), do not evaluate pulmonary fibrosis degree.Pulmonary fibrosis degree=pulmonary fibrosis area/lung tissue area ×
100%.
1.2.4 when IL-6 and TNF-α test experience are completed in serum, eyeball takes blood, and serum, detection step are retained in centrifugation
The rapid specification provided in strict accordance with kit is carried out.
1.2.5RT-pcr detection lung tissue type III collagen mrna expression Trizol methods extract each group lung tissue total serum IgE, core
Sour quantitative instrument determines the mass concentration (μ g/ml) and purity (A260/A280,1.8~2.0 between) of each group total serum IgE, quantitative inverse afterwards
Transcription synthesis cDNA (- 20 DEG C preservation), added during amplification in reaction system the μ l of Taq enzyme 6, the μ l of RNase-Free ddH2O 3,
Each 1 μ l of cDNA1 μ l, target gene upstream and downstream primer and each 1 μ l of internal reference β-actin upstream and downstream primers, totally 12 μ l systems.Setting
Good pre-degeneration, be denatured, anneal and extend the conditions such as each phase temperature and cycle-index after expanded.Amplified production is passed through
1.5% agarose gel electrophoresis, subsequent gel imaging system determines each group band gray value, by target gene band gray value with
β-actin are compared, and calculate relative expression's situation of each sample target gene.
1.2.6 immunohistochemical method determines the expression of TGF-β 1, P-Smad2 and α-SMA in mouse lung tissue by paraffin
Envision methods are used in section, and repairing liquid with 0.01M Tris-HCL carries out antigen retrieval.Primary antibody working solution concentration：The rabbit of TGF-β 1
Polyclonal antibody, P-smad2, α-SMA rabbit monoclonal antibodies 1:100, secondary antibody Zhong Shan Golden Bridge goat-anti rabbit immunohistochemical kit.
DAB develops the color, conventional dehydration, transparent, resinene mounting.All sections after immunohistochemical staining are carried out under identical conditions
The distribution of photographic analysis positive stained cells and the expression of albumen.Every section random selection 5 is regarded under 200 times of light microscopics
Open country, the accumulation OD value that positive reaction is surveyed under each visual field is determined using the image analysis softwares of Image-Pro Plus 6.0
IOD (sum) and area (sample sum), measures average optical density value=IOD (sum)/area (sample sum).With 5
The average value of the average optical density value in the visual field as this measured value.OD value shows more greatly destination protein expression more
It is high.
1.2.6 statistical procedures carry out single factor test using statistic software SPSS 17.0 to the experimental data at same time point
Variance analysis, P<0.05 is that difference is statistically significant.
2 results
As shown in Figure 1, 2, each time point alveolar structure of N group mouse is clear for 2.1 mouse lung tissue HE dyeing and inflammatory score,
Alveolar septum is normal.M groups mouse was destroyed in the 7th day alveolar structure, and inflammatory cell infiltration, alveolar septum is broadening, there is a small amount of red thin
Born of the same parents are oozed out, and have substantial amounts of macrophage, the significantly raised (P of alveolar inflammation scoring<0.05)；Alveolar inflammation has mitigated within 21st day,
But still have massive inflammatory cells infiltrated.Compared with M groups, corter pseudolaricis acetic acid group and positive controls pirfenidone group mouse alveolar structure
Destruction mitigates, and alveolar inflammation degree mitigates (P<0.05).
The lung compared with control group is showed under 2.2 mouse lung tissue Masson dyeing and Rating Model group mouse lung tissue light microscopic
Steep interstitial broadening, extracellular matrix also obvious hyperplasia has and largely contaminates green collagen fiber hyperplasia deposition, forms extensive fiber
Change；And corter pseudolaricis acetic acid group and positive controls mouse pulmonary fibrosis degree significantly mitigate compared with model group；Corter pseudolaricis acetic acid group is small
Mouse expression of collagen in lung fiber is deposited and positive controls (pirfenidone group) no difference of science of statistics (Fig. 3,4).
2.3 corter pseudolaricis acetic acids to fibrosis mice serum IL-6, the influence model group mice serum IL-6 of TNF-α content,
TNF-α content dramatically increases (p compared with control group<0.05)；Corter pseudolaricis acetic acid group blood serum IL-6, TNF-α content and model group phase
Than significantly reducing (p<0.05).(Fig. 5,6).Result above can prove that corter pseudolaricis acetic acid can effectively mitigate mouse inflammation journey
Degree.
Collagen of 2.4 corter pseudolaricis acetic acids to fibrosis mouse lung tissue type III collagen mrna expression model group mouse lung tissue
III significantly increases (p compared with control group<0.05)；Corter pseudolaricis acetic acid group can significantly reduce fibrosis mouse lung tissue Collage Ⅲ glomerulopathy
Expression.(Fig. 7,8)
2.5 corter pseudolaricis acetic acids to fibrosis mouse lung tissue α-SMA, TGF-β 1, P-smad2 contents influence
Model group mouse lung tissue α-SMA Average expression levels dramatically increase (p compared with control group<0.05)；Native rose of Sharon second
Acid group mouse lung tissue α-SMA Average expression levels significantly reduce (p compared with model group<0.05)；(Fig. 9, table 1)
Model group mouse lung tissue TGF-β 1, P-smad2 Average expression levels dramatically increase (p compared with control group<
0.05)；Corter pseudolaricis acetic acid can significantly reduce mouse lung tissue TGF-β 1, P-smad2 Average expression levels and show compared with model group
Write reduction (p<0.05).(Figure 10,11；Table 2,3)
Mouse lung tissue α-SMA the protein expressions of table 1 (n=5,)
Compared with N groups, * P<0.05；Compared with M groups, #P<0.05, F=11.058
The protein expression of 2 lung tissue TGF-β of table 1 (n=5,)
Compared with N groups, * P<0.05；Compared with M groups, #P<0.05, F=111.326
The mouse lung tissue P-smad2 protein expressions of table 3 (n=5,)
Compared with N groups, * P<0.05；Compared with M groups, #P<0.05, F=17.828
In summary, corter pseudolaricis acetic acid has significant protective effect to mouse pulmonary fibrosis.Its mechanism acted on may be with
Reduce collagen formation, reduce inflammation reaction, suppression TGF-β 1, P-smad2 up-regulation it is relevant.
Bibliography
[1] Du Yi treat the pharmacological research and Clinical advances Tianjin pharmacy .2015. of idiopathic pulmonary fibrosis medicine
(02):60-63.
[2] Raghu G, Collard HR, Egan JJ, et al.An official ATS/ERS/JRS/ALAT
statement:idiopathic pulmonary fibrosis:evidence-basedguidelines for
Diagnosis and management.Am J Respir Crit CareMed, 2011,183:788-824.
[3] Liu Bin, Zhang Yuhua, Wei Luqing, Li Zhenhua Atorvastatins are to lung fibrosis in rats MMP-9 and TIMP-1 table
The influence preclinical medicines reached and clinical, 2011,31 (1):91-92.
[4] Lu Y, Azad N, Wang L, et al.Phosphatidylinositol-3-kinase/
Aktregulates bleomycin-induced fibroblast proliferation and
Collagenproduction.Am J Respir Cell Mol Biol, 2010,42:432-441.
[5] Du R, Xia L, Ning X, et al.Hypoxia-induced Bmi1promotes renaltubular
epithelial cell-mesenchymal transition and renal fibrosis viaPI3K/Akt
Signal.Mol Biol Cell, 2014,25:2650-2659.
[6] Qin J, Xie YY, Huang L, et al.Fluorofenidone inhibits
nicotinamideadeninedinucleotide phosphate oxidase via PI3K/Akt pathway in
Thepathogenesis of renal interstitial fibrosis.Nephrology (Carlton), 2013,18:
690-699.
[7] Xiang Weihong, Wang Lifeng, seedling fortune win the differential gene expression for waiting bleomycin inducing mouse pulmonary fibrosis models
The breathing of analysis of spectrum China and critical illness monitoring magazine, 2015,14:242-249.
[8] Li M, Hong L.Pseudolaric acid B exerts antitumor activity via
suppression of the Akt signaling pathway in HeLa cervical cancer cells.Mol
Med Rep.2015.12(2):2021-6.
Claims (2)
1. application of the corter pseudolaricis acetic acid in anti-fibrosis drug is prepared, it is characterized in that shown in the corter pseudolaricis acetic acid structure formula (I)：
2. application of the preparation containing corter pseudolaricis acetic acid in anti-fibrosis drug is prepared, it is characterized in that the system containing corter pseudolaricis acetic acid
The formulation of agent is tablet, capsule, granule or injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610932447.1A CN107041882A (en) | 2016-10-31 | 2016-10-31 | Application of the corter pseudolaricis acetic acid in anti-fibrosis drug is prepared |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610932447.1A CN107041882A (en) | 2016-10-31 | 2016-10-31 | Application of the corter pseudolaricis acetic acid in anti-fibrosis drug is prepared |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107041882A true CN107041882A (en) | 2017-08-15 |
Family
ID=59543674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610932447.1A Pending CN107041882A (en) | 2016-10-31 | 2016-10-31 | Application of the corter pseudolaricis acetic acid in anti-fibrosis drug is prepared |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107041882A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107714688A (en) * | 2017-10-25 | 2018-02-23 | 中国人民武装警察部队后勤学院 | The application of Decahydro-3,6,9-tris(methylene)azuleno[4,5-b and its preparation in anti-fibrosis drug is prepared |
| CN108524496A (en) * | 2018-03-09 | 2018-09-14 | 天津国际生物医药联合研究院 | Pseudolarix acid B is being prepared for treating the application in pulmonary fibrosis disease drug |
| CN108896695A (en) * | 2018-07-04 | 2018-11-27 | 广州白云山敬修堂药业股份有限公司 | The discrimination method of corter pseudolaricis in a kind of Chinese medicine compound prescription |
-
2016
- 2016-10-31 CN CN201610932447.1A patent/CN107041882A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| TING LI等: "Pseudolaric Acid B Suppresses T Lymphocyte Activation Through Inhibition of NF-kappa B Signaling Pathway and p38 Phosphorylation", 《JOURNAL OF CELLULAR BIOCHEMISTRY》 * |
| 于红: "核转录因子NF-κB与肺纤维化", 《中国实用内科杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107714688A (en) * | 2017-10-25 | 2018-02-23 | 中国人民武装警察部队后勤学院 | The application of Decahydro-3,6,9-tris(methylene)azuleno[4,5-b and its preparation in anti-fibrosis drug is prepared |
| CN108524496A (en) * | 2018-03-09 | 2018-09-14 | 天津国际生物医药联合研究院 | Pseudolarix acid B is being prepared for treating the application in pulmonary fibrosis disease drug |
| CN108896695A (en) * | 2018-07-04 | 2018-11-27 | 广州白云山敬修堂药业股份有限公司 | The discrimination method of corter pseudolaricis in a kind of Chinese medicine compound prescription |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lam et al. | Neuroprotective effects of tanshinones in transient focal cerebral ischemia in mice | |
| Xia et al. | Hepatocyte growth factor attenuates liver fibrosis induced by bile duct ligation | |
| Zeng et al. | Dasatinib ameliorates chronic pancreatitis induced by caerulein via anti-fibrotic and anti-inflammatory mechanism | |
| CN107041882A (en) | Application of the corter pseudolaricis acetic acid in anti-fibrosis drug is prepared | |
| Wang et al. | Fibroblast growth factor 21 ameliorates pancreatic fibrogenesis via regulating polarization of macrophages | |
| Wei et al. | Targeting spike protein-induced TLR/NET axis by COVID-19 therapeutic NRICM102 ameliorates pulmonary embolism and fibrosis | |
| Wu et al. | Effect and mechanism of Qingfei Paidu decoction in the management of pulmonary fibrosis and COVID-19 | |
| Yang et al. | Protective effects of dioscin on vascular remodeling in pulmonary arterial hypertension via adjusting GRB2/ERK/PI3K-AKT signal | |
| CN106798737A (en) | Cryptotanshinone class and its application for preventing and treating pulmonary fibrosis | |
| Xue et al. | Carthami flos extract against carbon tetrachloride-induced liver fibrosis via alleviating angiogenesis in mice | |
| Fei et al. | Aldosterone alleviates lipopolysaccharide-induced acute lung injury by regulating epithelial sodium channel through PI3K/Akt/SGK1 signaling pathway | |
| Zhang et al. | 18β-Glycyrrhetinic acid monoglucuronide (GAMG) alleviates single-walled carbon nanotubes (SWCNT)-induced lung inflammation and fibrosis in mice through PI3K/AKT/NF-κB signaling pathway | |
| Guan et al. | Kaempferol inhibits renal fibrosis by suppression of the sonic hedgehog signaling pathway | |
| Li et al. | Fufang Shenhua tablet inhibits renal fibrosis by inhibiting PI3K/AKT | |
| Ma et al. | Anemoside B4 prevents chronic obstructive pulmonary disease through alleviating cigarette smoke-induced inflammatory response and airway epithelial hyperplasia | |
| Liu et al. | Radix Rehmannia Glutinosa inhibits the development of renal fibrosis by regulating miR-122-5p/PKM axis | |
| Zhu et al. | The key target and molecular mechanism of the volatile component of Scutellaria baicalensis Georgi in acute lung injury based on network pharmacology | |
| CN114767698A (en) | Use of dioscin in preparation of medicine for treating respiratory system diseases | |
| CN103919757B (en) | The medical usage of alkannin derivatives | |
| Jiao et al. | Irisin attenuates fine particulate matter induced acute lung injury by regulating Nod2/NF-κB signaling pathway | |
| Jin et al. | Corilagin attenuates airway inflammation and collagen deposition in ovalbumin-induced asthmatic mice | |
| CN115845021B (en) | A Chinese medicinal composition for preventing and treating pulmonary fibrosis, and its preparation method | |
| Peng et al. | NEK2 overexpression aggravates IL-22-induced keratinocyte proliferation and cytokine level increases and IMQ-induced psoriasis-like dermatitis | |
| TWI818466B (en) | Flavonoids for the treatment of arsenic induced lung damage | |
| Yoo et al. | Anti-septic effects of phenolic glycosides from Rhododendron brachycarpum in vitro and in vivo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170815 |
|
| RJ01 | Rejection of invention patent application after publication |